Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Antibacterial
    (1)
  • Antibiotic
    (1)
  • Antifection
    (1)
  • Apoptosis
    (1)
  • DNA/RNA Synthesis
    (1)
  • HSV
    (1)
  • Others
    (3)
Filter
Search Result
Results for "

anti-herpetic

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    6
    TargetMol | Activity
  • Inhibitory Antibodies
    1
    TargetMol | inventory
Acyclovir
T145459277-89-3
Acyclovir (Aciclovir) is a synthetic analog of the purine nucleoside, guanosine, with potent antiviral activity against herpes simplex viruses type 1 and 2, varicella-zoster virus and other viruses of the herpesvirus family.
  • $39
In Stock
Size
QTY
TargetMol | Inhibitor Sale
TargetMol | Citations Cited
Eprociclovir
T31659145512-85-2In house
Eprociclovir (A-5021) is a novel acyclovir analog that is a potent inhibitor of EHV1 replication and may be used for the treatment and/or prevention of infections with this virus.Eprociclovir has potent anti-herpetic activity against most human herpesviruses.
  • $160
In Stock
Size
QTY
Eprociclovir potassium
T70027219657-37-1
Eprociclovir potassium is a new acyclovir analogue and a potent inhibitor of EHV1 replication and may have potential for the treatment and/or prophylaxis of infections with this virus. Eprociclovir possess potent anti-herpetic activity against most human herpesviruses. A-5021 proved to be about 15-fold more potent than acyclovir in inhibiting viral replication. Eprociclovir inhibits murine herpetic keratitis. A-5021 eyedrops, which are easily applied onto the affected cornea, ameliorated clinical scores and suppressed virus growth. Eprociclovir is a promising alternative treatment of herpetic keratitis.
  • $2,270
1-2 weeks
Size
QTY
Tanezumab
T78282880266-57-9
Tanezumab (RN-624) is a high-affinity, specific humanized anti-NGF monoclonal antibody (mAb) that inhibits nerve growth factor (NGF) from binding to its p75 and TrkA receptors in the peripheral nervous system. It is used in research investigating both acute and chronic pain conditions, including osteoarthritis, knee pain, neuralgia, and post-herpetic neuralgia [1] [2].
  • Inquiry Price
Size
QTY
Eprociclovir Na
T69817219657-36-0
Eprociclovir Na is the salt form of Eprociclovir, also known as A-5021, a new acyclovir analogue and a potent inhibitor of EHV1 replication and may have potential for the treatment and/or prophylaxis of infections with this virus. Eprociclovir possess potent anti-herpetic activity against most human herpesviruses. A-5021 proved to be about 15-fold more potent than acyclovir in inhibiting viral replication. Eprociclovir inhibits murine herpetic keratitis. A-5021 eyedrops, which are easily applied onto the affected cornea, ameliorated clinical scores and suppressed virus growth. Eprociclovir is a promising alternative treatment of herpetic keratitis.
  • $2,270
10-14 weeks
Size
QTY
Eprociclovir dihydrate
T68957635678-85-2
Eprociclovir dihydrate is a new acyclovir analogue and a potent inhibitor of EHV1 replication and may have potential for the treatment and/or prophylaxis of infections with this virus. Eprociclovir possess potent anti-herpetic activity against most human herpesviruses. A-5021 proved to be about 15-fold more potent than acyclovir in inhibiting viral replication. Eprociclovir inhibits murine herpetic keratitis. A-5021 eyedrops, which are easily applied onto the affected cornea, ameliorated clinical scores and suppressed virus growth. Eprociclovir is a promising alternative treatment of herpetic keratitis.
  • $1,670
6-8 weeks
Size
QTY